[1] YOUNOSSI Z M, KOENIG A B, ABDELATIFET D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
[2] CORESH, J.Update on the burden of CKD[J]. J Am Soc Nephrol, 2017, 28(4):1020-1022.
[3] IX J H, SHARMA K.Mechanisms linking obesity, chronic kidney disease, and fatty liver disease:the roles of fetuin-A, adiponectin, and AMPK[J]. J Am Soc Nephrol, 2010, 21(4):406-412.
[4] ADAMS, L A, ANSTEE, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66(6):1138-1153.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.《非酒精性脂肪性肝病防治指南2018年更新版》[J]. 实用肝脏病杂志, 2018, 2(21):177-186.
[6] CHALASANI N, YOUNOSSI Z, LAVINE J E, et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Disease, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6):2005-2023.
[7] BALAKRISHNAN M, PATEL P, DUNN-VALADEZ S, et al. Women have lower risk of nonalcoholic fatty liver disease but higher risk of progression vs men:a systematic review and meta-analysis[J]. Clinical Gastroenterology and Hepatology, 2021, 19(1):61-71.
[8] 王春萍, 修桂英.长春地区健康体检人群中非酒精性脂肪肝的患病率及危险因素分析[J]. 临床研究, 2016, 11(11):139-141.
[9] MANTOVANI A, ZAZA G, BYRNE C D, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease:a systematic review and meta-analysis[J]. Metabolism, 2018, 79:64-76.
[10] 徐生志, 沈哲, 厉有名, 等.非酒精性单纯性脂肪肝与估计肾小球滤过率的相关性[J]. 中国老年学杂志, 2016, 4(36):1925-1927.
[11] BYRNE C D, TARGHER G.NAFLD as a driver of chronic kidney disease[J]. J Hepatol, 2020, 72(4):785-801.
[12] HRIBAL M L, PROCOPIO T, PETTA S, et al. Insulin Like Growth Factor-1, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease[J]. J Clin Endocrinol Metab 2013, 98(2):E304-E308.
[13] TARGHER G, CHONCHOL M, ZOPPINI G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease:is there a link?[J]. J Hepatol, 2011, 54(5):1020-1029.
[14] ZHU J Z, ZHOU Q Y, WANG Y M, et al. Prevalence of fatty liver disease and the economy in China:a systematic review[J]. World J Gastroenterol, 2015, 21(18):5695-5706.
[15] JOYCE T, CHIRINO Y I, NATALIA M T, et al. Renal damage in the metabolic syndrome(MetSx):disorders implicated[J]. Eur J Pharmacol, 2018, 818:554-568.
[16] YOUNG E C, HYUNG J K, YU B C, et al. Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease[J]. Sci Rep, 2020, 10(1):89-96.
[17] 张小铨, 王鑫蕾, 袁瑾, 等.2型糖尿病患者一相胰岛素分泌功能特点与糖尿病微血管病变的相关性[J]. 第二军医大学学报, 2018, 39(12):1348-1353.
[18] KOH E, KIM M, KIM M K, et al. Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease:a nationwide population-based study[J]. Atherosclerosis, 2019, 5(18):135-141.
[19] MUSSO G, CASSADER M, COHNEY S, et al. Emerging liver-kidney interactions in nonalcoholic fatty liver disease[J]. Trends Mol Med, 2015, 21(10):645-662. |